CAS
PCRX icon

Coppell Advisory Solutions’s Pacira BioSciences PCRX Stock Holding History

Coppell Advisory Solutions’s Portfolio PCRX Stock Details PCRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$5.59M Buy
+16
New +$378 0.46% 39
2024
Q3 		– Sell
-58
Closed -$1.66K – 1941
2024
Q2 		$1.66K Buy
+58
New +$1.65K ﹤0.01% 1411

Other funds holding PCRX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
DPCM
Doma Perpetual Capital Management Miami, Florida $431M AUM 13.21% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Coppell Advisory Solutions's PCRX Position: Q2 2026 in Review

Coppell Advisory Solutions opened a new position in Pacira BioSciences (PCRX) in Q2 2026: 16 shares worth $5.59M. The stake represents 0.46% of the portfolio and ranks #39 among its holdings. This is a return to the name: Coppell Advisory Solutions previously reported a position in PCRX as recently as Q2 2024.

Coppell Advisory Solutions first reported a position in PCRX in Q2 2024 and has held it in 2 quarters since. 254 funds tracked by Wall St. Rank hold PCRX as of Q2 2026.

  • Coppell Advisory Solutions held 16 shares of Pacira BioSciences worth $5.59M as of Q2 2026.
  • Pacira BioSciences was a new Coppell Advisory Solutions position in Q2 2026.
  • Pacira BioSciences made up 0.46% of Coppell Advisory Solutions's portfolio in Q2 2026, its #39 holding.
  • Coppell Advisory Solutions first reported a position in Pacira BioSciences in Q2 2024 and has held it in 2 quarters since.
  • 254 funds tracked by Wall St. Rank held Pacira BioSciences as of Q2 2026.

Based on Coppell Advisory Solutions's 13F filing for Q2 2026, filed 14 Aug 2026.